Risk.net

DrKW adds to New York sales effort

Dresdner Kleinwort Wasserstein (DrKW) has continued its sales build-up with four new hires to its team in New York this month, said a spokesperson for the bank.

    • Sophie Brown
  • LinkedIn  
  • Save this article
  • Print this page  
Gordon Bowling and Jennifer Ropiak both joined today. Bowling will focus on selling fixed-income products to central bank clients. He leaves UBS in New York, where he held a similar position. Ropiak will cover commodities, with particular emphasis on platinum group metals. She leaves AIG in Greenwich.

Diva Singh is also set to join DrKW in the coming weeks. She will focus on foreign exchange sales to hedge fund clients and joins from Merrill Lynch.

Meanwhile, Hannah Clements joined on September 2 as an analyst in DrKW's Capital Markets group in New York. She covers FX sales, with particular focus on e-FX.

All report to Ricardo Zulliger, head of FX and liquid market sales in New York.These hires follow four sales hires to the London office earlier this month.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Copyright Infopro Digital Limited. All rights reserved.

As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.

If you would like to purchase additional rights please email info@risk.net

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.

If you would like to purchase additional rights please email info@risk.net

More on People

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here